Travere Inventory from 2010 to 2025

TVTX Stock  USD 22.91  0.81  3.41%   
Travere Therapeutics Inventory yearly trend continues to be fairly stable with very little volatility. Inventory will likely drop to about 6 M in 2025. During the period from 2010 to 2025, Travere Therapeutics Inventory regression line of annual values had r-squared of  0.84 and arithmetic mean of  4,655,154. View All Fundamentals
 
Inventory  
First Reported
2014-03-31
Previous Quarter
M
Current Value
6.4 M
Quarterly Volatility
3.9 M
 
Yuan Drop
 
Covid
Check Travere Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Travere Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 16.4 M, Selling General Administrative of 320.6 M or Other Operating Expenses of 630.3 M, as well as many indicators such as Price To Sales Ratio of 6.88, Dividend Yield of 0.0 or PTB Ratio of 3.63. Travere financial statements analysis is a perfect complement when working with Travere Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Travere Therapeutics Correlation against competitors.
For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Latest Travere Therapeutics' Inventory Growth Pattern

Below is the plot of the Inventory of Travere Therapeutics over the last few years. It is Travere Therapeutics' Inventory historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Travere Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Inventory10 Years Trend
Slightly volatile
   Inventory   
       Timeline  

Travere Inventory Regression Statistics

Arithmetic Mean4,655,154
Geometric Mean3,164,687
Coefficient Of Variation72.09
Mean Deviation2,902,693
Median5,619,000
Standard Deviation3,355,764
Sample Variance11.3T
Range10M
R-Value0.92
Mean Square Error1.9T
R-Squared0.84
Slope645,468
Total Sum of Squares168.9T

Travere Inventory History

2025M
202410.8 M
20239.4 M
20226.9 M
20217.3 M
20207.6 M
20196.1 M

Other Fundumenentals of Travere Therapeutics

Travere Therapeutics Inventory component correlations

About Travere Therapeutics Financial Statements

Travere Therapeutics investors use historical fundamental indicators, such as Travere Therapeutics' Inventory, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Travere Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Inventory10.8 MM
Change To Inventory-35.5 M-33.7 M
Inventory Turnover 1.10  0.78 
Days Of Inventory On Hand 344.96  437.62 
Average Inventory1.5 M827.4 K
Days Of Inventory Outstanding 344.96  437.62 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.